Johnson & Johnson
JNJ · NYSE · Healthcare
$269.17
$0.30 (-0.11%) today
Market Cap
$648.67B
24h Volume
$1.7B
P/E Ratio
31.3
52w High
$278.43
52w Low
$172.80
Est. AI Revenue
10%
7-Day Sparkline (Static)
Company facts
Performance
About Johnson & Johnson
Johnson & Johnson is one of the world's largest healthcare companies. It makes money from pharmaceuticals and medical devices, selling treatments and surgical products to health systems and patients worldwide.
Its AI efforts run through both arms. AI drug discovery tools support its pharmaceutical pipeline, surgical robotics AI underpins its medtech ambitions, MedTech AI analytics improve device performance, and clinical trial AI helps design and run studies.
Founded in 1886 and headquartered in New Brunswick, New Jersey, Johnson & Johnson trades on the NYSE and employs about 138,200 people.
Johnson & Johnson in the AI buildout
Johnson & Johnson sits in the AI Healthcare and Robotics & Automation layers of the AI buildout. Its surgical robotics program, including the Ottava robot in development, gives it real exposure to AI-assisted surgery, and it applies AI to drug discovery, clinical trials, and medtech analytics. That exposure is small relative to the whole: the thesis rests on pharmaceutical and device franchises whose demand has nothing to do with the buildout. AI is a capability inside a healthcare giant.
JNJ is tracked in AI Healthcare and Robotics & Automation, rated Peripheral on the AI Exposure leaderboard.
By the numbers
52-week range
JNJ trades at $269.17, 91% of the way up its 52-week range of $172.80 to $278.43.
Market cap
Market capitalization is $648.67B, with an AI Exposure Score of 12 out of 100.
Valuation vs peers
Its P/E ratio of 31.3 is in line with the AI Healthcare category median of 29.6.
Next earnings
Johnson & Johnson is next expected to report earnings on October 13, 2026.
Market data as of the close on . Prices are end of day, not live.
Frequently asked questions
What does Johnson & Johnson do?
Johnson & Johnson sells pharmaceuticals and medical devices worldwide. It applies AI to drug discovery, clinical trials, and medtech analytics, and is developing the Ottava surgical robot.
How is Johnson & Johnson exposed to AI?
Modestly. Surgical robotics and AI drug discovery give real but small exposure inside a business driven by drug and device franchises. Supercycle rates it an AI Exposure Score of 12 out of 100.
What are Johnson & Johnson's main AI efforts?
AI drug discovery for its pharmaceutical pipeline, surgical robotics AI including the Ottava program, MedTech AI analytics for devices, and clinical trial AI for study design.
Is JNJ a pure play AI stock?
No. Johnson & Johnson is a diversified healthcare company where AI supports the pipeline and devices rather than driving demand. Its AI Exposure Score of 12 out of 100 reflects that.
Where is Johnson & Johnson based and who leads it?
Johnson & Johnson is headquartered in New Brunswick, New Jersey, and is led by CEO Joaquin Duato. The company was founded in 1886 and employs about 138,200 people.
Profile written 2026-08, updated as the business changes. Editorial content, not investment advice.